Oct
2019

NIH/NCATS and PreComb’s joint article published in SLAS Discovery

Hombrechtikon, October 29th, 2019

3D tumor models not only better reflect the spatial environment of the native tumor, but also allow information on efficacy and toxicity to be obtained in parallel from the same model. I would therefore like to thank my former InSphero team and the cooperation partners of NIH/NCATS and the Technical University of Aachen as well as Promega and Lonza for the successful development and publication of such an application for high throughput screening. For those interested, you can find the publication “A 3D Heterotypic Multicellular Tumor Spheroid Assay Platform to Discriminate Drug Effects on Stroma versus Cancer Cells” on the website of the following publisher: https://doi.org/10.1177/2472555219880194

PreComb Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com

Jun
2019

PreComb joins the Society of Functional Precision Medicine

Hombrechtikon, June 28th, 2019

The Society for Functional Precision Medicine (Sf(PM)), chaired by Prof. Tony Letai of the Dana-Farber Cancer Institute, was established in recognition of the urgent need for matching cancer patients with the best personal therapy. The society aims to form a community to bring together scientists, physicians and companies leading the field of functional precision medicine. PreComb is joining the newly formed Society and is proud to be at the forefront of this new wave of personalized cancer treatment

https://www.sfpm.io/

Supplementary information:
Tony Letai has provided insights into genomic profiling in a enlightening podcast: Listen to Podcast​

Feb
2019

NIH/NCATS and PreComb’s joint FEATURE article published in Drug Discovery Today

Wädenswil, February 11th, 2019

In times of exploding drug discovery and development costs 3D technologies to create ex vivo human tissues, organs, disease models and micro-physiological systems have the potential to reshape drug development. Together with the NIH/NCATS, PreComb has published a FEATURE article in in the January edition of “Drug Discovery Today” outlining what steps should be taken to exploit the 3D potential. A strategy is outlined for novel 3D-tailored holistic drug discovery concepts rather than piecemeal integration of 3D models into the current processes.

About NIH – NCATS

The National Center for Advancing Translational Sciences (NCATS) was established with the focus to transform the translational science process to enable faster delivery of new treatments for patients. It is one of 27 Institutes and Centers at the US National Institutes of Health (NIH).

PreComb Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com

Jan
2019

PreComb funded bachelor thesis won Lab Science Award 2019

Wädenswil, January 29th, 2019

In recognition of her excellent bachelor thesis in the field of Life Sciences and Diagnostics, Toolpoint and the VHB Foundation awarded Ms. Dafina Ismaili with the Lab Science Award 2019. Her work on “Heterotypic multicellular tumor spheroids and their use in the evaluation of combination therapies” was funded by PreComb Therapeutics and conducted at the Centre for Cell Biology and Tissue Engineering at the University of Applied Sciences (ZHAW) in Wädenswil, Switzerland.

The award ceremony will take place at this year’s Swiss Symposium on Lab Automation at the University of Applied Sciences Rapperswil (HSR).

We congratulate Ms. Ismaili, the ZHAW Centre for Cell Biology and Tissue Engineering and the Group of 3D Tissues and Biofabrication for this success and the excellent collaboration.

Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com

Oct
2018

PreComb Therapeutics appoints Dr. Andrew Thomas as Strategic Advisor

Wädenswil, October 18th, 2018

PreComb, the leader in 3D microtumor combinatorial drug discovery, is excited to announce the appointment of Dr. Andrew Thomas as a new member of the Strategic Advisory Board. Dr. Thomas brings a wealth of expertise from over 20 year of key positions in global Pharma companies and small molecule drug discovery and development.

Dr. Thomas has previously been Global Head of Medicinal Chemistry at Roche, being responsible for creating and developing an innovative portfolio of small molecule medicines for Neuroscience, Ophthalmology, Rare Diseases, Inflammation, Infectious Diseases, Immunology and Oncology. He is a founder and executive partner of IPSO group, Investment Director at Helvetica Capital and an active driver of the Swiss Entrepreneurs Foundation.
“We are proud to welcome Andrew in our Advisory Board” said Jens Kelm, CEO of PreComb. “His wealth of pharma experience in drug discovery and development and his entrepreneurial thinking will add tremendous value to our company and our mission to deliver novel combination therapies for difficult to treat cancers.”

About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtumor cultures to enable high-throughput 3D combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.

Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com

Sep
2018

PreComb announces the formation of the Strategic Advisory Board

Wädenswil, September 21st, 2018

 
PreComb, the leader in micro-tumor based drug discovery, today announced the formation of its new advisory board, a strategic committee of trusted advisors.

“The search for experienced Advisory Board members to support the development of PreComb has been a thoughtful exercise” said Jens M. Kelm, CEO of PreComb Therapeutics. “We’ve been very fortunate to attract highly networked advisors with extensive practical experiences in Biotech industry, preclinical and clinical cancer research. We are looking forward to work with our advisors to quickly implement our ideas and leverage their expertise to develop novel anti-cancer combination therapies.

Appointments of the Strategic advisory board include:

Dominik Escher, PhD – Founding partner of Puros Bioventures and former founder and CEO of ESBATech AG

Prof. Heinz Zwierzina, MD – Head of the Early Clinical Trial Unit within the Department for Haematology and Oncology at the University Hospital, Innsbruck

Prof. Laura Suter-Dick, PhD – Professor for Molecular Toxicology at the University of Applied Sciences Northwestern Switzerland (FHNW)

About PreComb Therapeutics

PreComb Therapeutics AG is a swiss-based biotechnology company focusing on the development of novel combination therapies, primarily for the use in oncology and immuno-oncology. PreComb is developing a phenotypical drug development platform using 3D microtissue culture to enable high-throughput combinatorial drug screening. The platform shall deliver more efficient cancer therapies to substantially improve long-term prognosis and quality-of-life for patients.

For more Information about PreComb Therapeutics, please visit https://www.precomb.com or follow us on LinkedIn.

Media contact

PreComb Therapeutics AG
Dr. Peter Steiner
info@precomb.com

Close Menu